NASDAQ:OTLK

Outlook Therapeutics Stock Insider Trading

etoro logo Buy OTLK
*Your capital is at risk
$0.81
-0.0038 (-0.467%)
At Close: Jun 03, 2026

Outlook Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 67.08. In total, the insiders bought 83.96M and sold 18.95M OTLK shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
67.08
Buy 83.96M shares
Sell 18.95M shares
96% Buy Activity
Negligible or No Correlation
Buy Signal High Confidence
May 28, 2026

Analysis Breakdown:

  • Strongly supported by a very high Insider Power Score of 67.08.
  • Confidence increased due to high data reliability score of 100.
  • Supported by overwhelming buy-side pressure (96% buys).

Historical Insider Trades

Date Type Person Role Amount
May 28, 2026
Sell
Warrants (right to buy)
H-ExpireLong
Sukhtian Ghiath M.
Director 8 571 428
Value: $12.0M
May 28, 2026
Buy
Common Stock
P-Purchase
Sukhtian Ghiath M.
Director 8 539 709
Value: $5.00M
May 28, 2026
Buy
Warrants (right to buy)
P-Purchase
Sukhtian Ghiath M.
Director 8 571 428
Value: $5.02M
May 28, 2026
Buy
Warrants (right to buy)
P-Purchase
Sukhtian Ghiath M.
Director 3 458 571
Value: $2.02M
May 28, 2026
Sell
Warrants (right to buy)
H-ExpireLong
Sukhtian Ghiath M.
Director 3 458 571
Value: $7.82M
May 27, 2026
Buy
Common Stock
P-Purchase
Sukhtian Faisal Ghiath
Director
Director 122 174
Value: $50.0K
May 26, 2026
Buy
Common Stock
P-Purchase
Hilzinger Kurt J
Director
Director 400 000
Value: $176.5K
May 26, 2026
Buy
Common Stock
P-Purchase
Haddadin Yezan Munther
Director
Director 34 000
Value: $15.0K
May 26, 2026
Buy
Common Stock
P-Purchase
Thurman Randy H
Director
Director 5 000
Value: $2K
Oct 03, 2025
Buy
Stock Option (Right to Buy)
A-Award
Huang Andong
Director
Director 53 316
Value: $56.5K
Oct 03, 2025
Buy
Stock Option (Right to Buy)
A-Award
Haller Julia A
Director
Director 58 648
Value: $62.2K
Oct 03, 2025
Buy
Stock Option (Right to Buy)
A-Award
Hilzinger Kurt J
Director
Director 90 638
Value: $96.1K
Oct 03, 2025
Buy
Stock Option (Right to Buy)
A-Award
Haddadin Yezan Munther
Director
Director 95 969
Value: $101.7K
Oct 03, 2025
Buy
Stock Option (Right to Buy)
A-Award
Auffarth Gerd
Director
Director 58 648
Value: $62.2K
Oct 03, 2025
Buy
Stock Option (Right to Buy)
A-Award
Sukhtian Faisal Ghiath
Director
Director 117 296
Value: $124.3K
Oct 03, 2025
Buy
Stock Option (Right to Buy)
A-Award
Sukhtian Faisal Ghiath
Director
Director 117 296
Value: $124.3K
Oct 03, 2025
Buy
Stock Option (Right to Buy)
A-Award
Auffarth Gerd
Director
Director 58 648
Value: $62.2K
Oct 03, 2025
Buy
Stock Option (Right to Buy)
A-Award
Haddadin Yezan Munther
Director
Director 95 969
Value: $101.7K
Oct 03, 2025
Buy
Stock Option (Right to Buy)
A-Award
Hilzinger Kurt J
Director
Director 90 638
Value: $96.1K
Oct 03, 2025
Buy
Stock Option (Right to Buy)
A-Award
Haller Julia A
Director
Director 58 648
Value: $62.2K
Oct 03, 2025
Buy
Stock Option (Right to Buy)
A-Award
Huang Andong
Director
Director 53 316
Value: $56.5K
Oct 01, 2025
Buy
Stock Option (Right to Buy)
A-Award
Huang Andong
Director
Director 286 734
Value: $298.2K
Oct 01, 2025
Buy
Stock Option (Right to Buy)
A-Award
Haller Julia A
Director
Director 286 734
Value: $298.2K
Oct 01, 2025
Buy
Stock Option (Right to Buy)
A-Award
Hilzinger Kurt J
Director
Director 286 734
Value: $298.2K
Oct 01, 2025
Buy
Stock Option (Right to Buy)
A-Award
Gangolli Julian S
Director
Director 286 734
Value: $298.2K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT OUTLOOK THERAPEUTICS INC.
Outlook Therapeutics
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and lice...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE